Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor microenvironment that has rendered it largely refractory to immunotherapy. We used single-cell RNA sequencing on patient tumors and matched blood, and we uncovered a previously unappreciated, complex environment of immune-suppressive cellular interactions. These experiments reveal immune checkpoint expression heterogeneity on individual patient T cells, with corresponding ligands on neoplastic and myeloid cells. TIGIT was upregulated on tumor infiltrating CD8+ T cells and was the only checkpoint receptor consistently expressed by exhausted CD8+ T cells. Clinical annotation of the samples revealed that the exhausted signature is most prominent in patients with advanced stages of disease. Our findings suggest individualized combination therapy, involving anti-TIGIT therapies, may be necessary to extend the benefits of immunotherapy to pancreatic cancer patients.

Authorized Access
Publicly Available Data (Public ftp)
Study Inclusion/Exclusion Criteria

Inclusion criteria:

  1. Patient must be at least 18 years old.
  2. Patients being seen or previously treated within the University of Michigan Health System and/or the Comprehensive Cancer Center.
  3. Patient must be willing and able to provide written informed consent.

Exclusion criteria:

  1. Doesn't meet inclusion criteria

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Links to Related Resources
Authorized Data Access Requests
Study Attribution
  • Principal Investigator
    • Marina Pasca di Magliano, PhD. University of Michigan, Ann Arbor, MI, USA.
  • Funding Sources
    • R01CA151588. National Institutes of Health, Bethesda, MD, USA.
    • R01CA198074. National Institutes of Health, Bethesda, MD, USA.
    • U01CA224145. National Institutes of Health, Bethesda, MD, USA.